Methods of reducing mammographic breast density and/or breast cancer risk
The present disclosure is directed to generally methods and/or compositions for treating mammographic breast density and/or breast stiffness in a patient in need thereof, such as a pre-menopausal, a peri-menopausal or a post-menopausal patient, comprising the administration of an effective amount of androgenic agent and an effective amount of an aromatase inhibitor. The present disclosure is also directed to methods and/or compositions for reducing breast pain. The present disclosure is also directed to method and/or compositions for reducing elasticity and/or decreasing mechano-transduction on the genome of breast cells. The present disclosure is also directed to methods and/or compositions for stabilizing and/or increasing the levels of androgen receptor expression in breast tissue.
1. 1 . A method of reducing background parenchymal enhancement (BPE) in a patient in need thereof, comprising administering to the patient:
i) an effective amount of androgenic agent selected from the group consisting of testosterone, methyltestosterone, testosterone undecanoate, testosterone propionate, testosterone cypionate, and testosterone enanthate; and
ii) an effective amount of an aromatase inhibitor selected from the group consisting of: exemestane, formestane, anastrozole, letrozole, vorozole, and fadrozole;
wherein the method mitigates the treated patient's risk of developing breast cancer.
2. The method of claim 1 , wherein the effective amount of androgenic agent is testosterone and the effective amount of the aromatase inhibitor is anastrozole and is administered by subcutaneous implant.
3. The method of claim 2 , wherein:
i) the effective amount of the testosterone is 2-200 mg; and
ii) the effective amount of the anastrozole is 0.5-10 mg.
4. The method of claim 3 , wherein the method improves breast compression during mammographic visualization or detection of the breast between one or more annual intervening mammographic detections.
5. The method of claim 3 , wherein the method stabilizes and/or increases levels of androgen receptor expression in breast tissue in at least one of the patient's breasts between one or more annual intervening mammographic detections.
6. The method of claim 3 , wherein the patient is pre-menopausal.
7. The method of claim 3 , wherein the patient is peri-menopausal.
8. The method of claim 3 , wherein the BPE reduces by at least 1 Breast Imaging-Reporting and Data System (BI-RADS®) level after 1 year, 2 years, 3 years, 4 years or 5 years of treatment.
9. The method of claim 8 , wherein the BPE reduces by at least 2 BI-RADS® levels after 1 year, 2 years, 3 years, 4 years or 5 years of treatment.